Compare EXAS & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXAS | HSIC |
|---|---|---|
| Founded | 1995 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3B | 8.8B |
| IPO Year | N/A | 1995 |
| Metric | EXAS | HSIC |
|---|---|---|
| Price | $101.56 | $76.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 14 |
| Target Price | ★ $77.94 | $76.50 |
| AVG Volume (30 Days) | ★ 5.2M | 1.2M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.70 |
| EPS | N/A | ★ 3.17 |
| Revenue | $3,082,033,000.00 | ★ $12,938,000,000.00 |
| Revenue This Year | $19.40 | $5.35 |
| Revenue Next Year | $13.51 | $3.34 |
| P/E Ratio | ★ N/A | $24.04 |
| Revenue Growth | ★ 14.47 | 3.51 |
| 52 Week Low | $38.81 | $60.56 |
| 52 Week High | $102.66 | $82.49 |
| Indicator | EXAS | HSIC |
|---|---|---|
| Relative Strength Index (RSI) | 85.02 | 58.78 |
| Support Level | $101.45 | $76.27 |
| Resistance Level | $101.88 | $78.10 |
| Average True Range (ATR) | 0.36 | 1.28 |
| MACD | -1.35 | -0.21 |
| Stochastic Oscillator | 61.00 | 64.19 |
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.